Dr. O'Malley on Toxicity Profiles of PARP Inhibitors in Ovarian Cancer

OncLiveTV
04 Nov, 2019 ,

Dr. O’Malley discusses the toxicities associated with PARP inhibitors in ovarian cancer. According to O’Malley, veliparib, niraparib (Zejula), olaparib (Lynparza), and rucaparib (Rubraca) have similar toxicities. All 4 PARP inhibitors are associated with gastrointestinal adverse events (AEs) such as nausea and constitutional AEs such as fatigue, which explains O’Malley.